Antibodies
2 March 2015
FDA Grants Priority Review for Asfotase Alfa as a Treatment for Patients with Hypophosphatasia28 February 2015
WuXi Congratulates TaiMed Biologics on Receiving Breakthrough Therapy Designation from U.S. FDA28 February 2015
Positive phase II data highlights benefits of Alcon’s RTH258 for patients with neovascular (wet) age-related macular degeneration27 February 2015
Alexion Receives CHMP Positive Opinions for Important Updates to the EU Label for Soliris® (eculizumab)27 February 2015
Biogen Idec and Sobi Announce Positive Top-Line Efficacy and Safety Results from Phase 3 ALPROLIX® Pediatric Study26 February 2015
Progenics Pharmaceuticals Presents Positive Phase 2 Data for PSMA ADC in Metastatic Castration-Resistant Prostate Cancer24 February 2015
Teva Announces Positive Results for TEV-48125 in Phase IIb Chronic Migraine Study Meeting Primary and Secondary Endpoints17 February 2015
Seattle Genetics Advances Immuno-Oncology Program SEA-CD40 Into Phase 1 Clinical Trial for Advanced Solid Tumors16 February 2015
Hospira launches first biosimilar monoclonal antibody (mAb) Inflectra™ (infliximab) in major European markets12 February 2015
Elusys Reports Efficacy of Its Anthrax Anti-Toxin in Post-Exposure Prophylaxis in Animal StudiesNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports